NCT00698516 - Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Recurrent Small-cell Lung Cancer (SCLC)Lung Cancer, Small Cell

Interventions

DRUG

Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)

2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.

Trial Locations (16)

GSK Investigational Site, Mt. Pleasant

GSK Investigational Site, Marietta

GSK Investigational Site, Athens

GSK Investigational Site, Macon

GSK Investigational Site, Gainesville

GSK Investigational Site, Naples

GSK Investigational Site, Nashville

GSK Investigational Site, Chattanooga

GSK Investigational Site, Memphis

GSK Investigational Site, Memphis

GSK Investigational Site, Jackson

GSK Investigational Site, Cincinnati

GSK Investigational Site, Madison

GSK Investigational Site, Jonesboro

GSK Investigational Site, Fort Worth

GSK Investigational Site, Seattle